www.Top100Medicine.com - TOP 100 MEDICAL SITES
TOP 100 MEDICAL SITES
 Main  |  Add a Site  |  FREE Content for Your Web-site  |  Bookmark this site  |  Links  |  Webmaster 
Updated Sun, August 22, 2010.
551.georges.dolisi.free.fr1850
552.www.ospedale.perugia.it1850
553.www.unaformec.org1840
554.www.mta-labor.info1830
555.www.fmed.ulaval.ca1830
556.ecm.sanita.it1830
557.www.mednemo.it1830
558.www.gerontologia.org1820
559.www.senefro.org1810
560.www.fnomceo.it1790
561.www.sip.it1790
562.www.koerperwelten.de1760
563.www.orthopedie.com1750
564.www.idi.it1740
565.www.femiboard.com1720
566.www.eurotransplant.nl1710
567.www.genou.com1710
568.www.hemodinamiadelsur.com.ar1700
569.www.soc-nephrologie.org1640
570.www.helloduck.com1630
571.www.diabetespartner.de1620
572.www.secardiologia.es1620
573.www.fdg.unimaas.nl1610
574.www.chirurgiatoracica.org1600
575.www.oncologia2000.com1580
576.www.cuore.iss.it1560
577.www.hsantalucia.it1550
578.www.medi-netz.com1540
579.www.aboutkidneystone.info1540
580.www.weballergies.com1530
581.www.centrum45.nl1530
582.www.aocd.org1520
583.look4.free.fr1500
584.www.aida.it1500
585.www.med.uniroma2.it1490
586.www.antonius.net1490
587.www.iugm.qc.ca1470
588.www.rees-france.com1460
589.www.qlmed.org1460
590.www.altrecht.nl1460
591.www.geneeskundestudent.nl1460
592.revista.seaic.es1440
593.www.doctor.am1440
594.www.mpipsykl.mpg.de1380
595.www.alrf.asso.fr1370
596.www.hospiten.es1370
597.www.ctrl.com1320
598.www.ospedale.al.it1320
599.www.isplad.org1310
600.www.usl8.toscana.it1310
Pages:  1  2  3  4  5  6  7  8  9  10  11  12 
 13  14  15  16 



Subscribe to RSS feed Subscribe to Feed Burner feed Add to Del.icio.us Add to Yahoo Add to Google Add to Reddit Add to Blink Add to Meneame Add to Fark Add to Newsvine

561. www.sip.it

Rating: 1790 points*
*amount mentions of word 'www.sip.it' on the other websites

www.sip.it

SIP - Società Italiana di Pediatria

Description: SIP - Società Italiana di Pediatria

Most popular searches: wwwsip.it, Pharmaceutical, www.sipit, Krankenhaus, medical information, Cardiac, medical research, ww.sip.it, genome, www.si.pit, SIP, ww.wsip.it, drug, family practice, www.sip.it, wwwsip.it, obesity, Immunology, drug rehab, www.sipi.t, www.isp.it, www.sip.t, ww.sip.it, blood pressure, Nachrichten, doctor, health care, medicine, physician, asthma, www.si.it, www.ip.it, vaccines, health, patient, cholesterol, Allergy, www.sip.ti, wwws.ip.it, www.spi.it, www.sp.it, www.sip.i, www.sip.it

Google

© 2005-2010 www.Top100Medicine.com
Curis' Cancer Therapy Arouses Curiosity
Kris Tuttle submits: It’s nearly impossible these days not to be personally touched by cancer. The disease has to be on the top of everyone’s list for finding new, more effective treatments. Putting our personal feelings aside for the moment, we also recognize that any company fielding a valuable new treatment in this area will deliver strong investment returns. However, even the best scientists in the world have differing opinions of what may or may not ultimately work. So we have to be careful in doing our research and limiting our risk in this area.Complete Story »
seekingalpha.com
FDA Warns on Cigarette Ban
FDA officials warned companies Tuesday to think twice about circumventing a new ban on certain flavored cigarettes by introducing similar products like little cigars.
online.barrons.com
Merck KGaA Tightens Outlook
The German pharmaceutical and chemical company tightened its financial outlook for 2009 after it reported a 28% fall in third-quarter net profit.
online.wsj.com
Sanofi-Aventis to Establish Venture Capital Fund, Looking for 'Right Brain Activity'
The Burrill Report submits: By Marie DaghlianChris Viehbacher, CEO of Sanofi-Aventis (SNY), said his company will establish a venture capital fund, joining an ever-growing queue of pharma venture capital funds seeking to gain better access biotech innovation. Viehbacher confirmed the French drugmaker’s plans in comments made at an event at Sanofi’s R&D campus in Cambridge, Massachusetts, the online publication Xconomy reported. The company also announced a significant expansion and extension of its collaboration with Regeneron Pharmaceuticals (REGN). The deal comes a month after Sanofi-Aventis struck a partnership deal with Merrimack Pharmaceuticals focused on the biotech's experimental antibody drug for cancer, and continues Sanofi's strategy of looking outside the company for what Viehbacher calls "right brain activity" that leads to creativity and innovation.Complete Story »
seekingalpha.com
Celgene Prelims Look Upbeat
Zacks.com submits: Yesterday, Celgene Corporation (CELG) announced preliminary (unaudited) results for the fourth quarter of fiscal 2009 (ended December 31). The company earned 62 cents per share, beating the Zacks Consensus Estimate by 5 cents. Celgene earned 43 cents in the year-ago quarter. The preliminary results indicate that the company earned $2.08 in fiscal 2009, up 33%. This is above the Zacks Consensus Estimate by 23 cents. The company will report full year results on January 28, 2010. The results revealed that revenues have jumped in excess of 20% to about $755 million. Sales of Revlimid, marketed as a treatment for multiple myeloma and myelodysplastic syndrome, increased nearly 35% in the quarter to about $495 million. Celgene is seeking to expand the Revlimid label. Fourth-quarter sales of Celgene’s cancer drug, Vidaza, registered a 65% year-over-year increase to about $115 million. Net sales of its other product, Thalomid, were around $105 million for the quarter.Complete Story »
seekingalpha.com